AB
MACK

Amalgamated Bank’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Amalgamated Bank’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-353
Closed -$5K – 3182
2024
Q1 		$5K Sell
353
-1,129
-76% -$15.9K ﹤0.01% 2757
2023
Q4 		$20K Sell
1,482
-105
-7% -$1.33K ﹤0.01% 2660
2023
Q3 		$20K Hold
1,587
– – ﹤0.01% 2669
2023
Q2 		$20K Buy
+1,587
New +$19.8K ﹤0.01% 2755
2017
Q3 		– Sell
-2,091
Closed -$20K – 1619
2017
Q2 		$20K Buy
2,091
+170
+9% +$3.47K ﹤0.01% 1581
2017
Q1 		$47K Buy
1,921
+1
+0.1% +$25 ﹤0.01% 1472
2016
Q4 		$62K Buy
1,920
+254
+15% +$10.8K ﹤0.01% 1475
2016
Q3 		$83K Buy
1,666
+7
+0.4% +$291 ﹤0.01% 1346
2016
Q2 		$67K Buy
1,659
+108
+7% +$5.88K ﹤0.01% 1348
2016
Q1 		$102K Buy
1,551
+150
+11% +$7.83K 0.01% 1221
2015
Q4 		$87K Sell
1,401
-69
-5% -$4.86K 0.01% 1151
2015
Q3 		$98K Buy
1,470
+23
+2% +$1.88K 0.01% 1241
2015
Q2 		$141K Buy
+1,447
New +$138K 0.01% 1287
2014
Q1 		– Sell
-1,275
Closed -$54K – 863
2013
Q4 		$54K Buy
+1,275
New +$37K 0.01% 818

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Amalgamated Bank's MACK Position: Q2 2024 in Review

Amalgamated Bank sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 353 shares — an estimated $5K sold.

Amalgamated Bank first reported a position in MACK in Q4 2013 and held it in 14 quarters. The position peaked at $141K in Q2 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Amalgamated Bank reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Amalgamated Bank sold 353 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $5K.
  • Amalgamated Bank first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2013 and held it in 14 quarters.
  • Amalgamated Bank's Merrimack Pharmaceuticals, Inc. position peaked at $141K in Q2 2015.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Amalgamated Bank's 13F filing for Q2 2024, filed 12 Aug 2024.